• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did CEO Exit Just Shift Bausch + Lomb (BLCO) Investment Narrative?

    Simply Wall St·10/25/2026 03:36:13
    語音播報
    • Bausch + Lomb reported that Brent Saunders stepped down as chief executive and director on October 12, 2026, with board chair Thomas J. Appio taking over as interim CEO while also remaining CEO of Bausch Health.
    • The move concentrates leadership of Bausch + Lomb and Bausch Health under Appio, which could influence how resources, product priorities and cost programs are coordinated across the broader eye care platform.
    • Next, the focus turns to how Bausch + Lomb’s investment narrative evolves as Thomas J. Appio steps in as interim chief executive.

    See how leadership shake-ups like Bausch + Lomb’s compare with other potential opportunities across our hand picked 21 high quality undiscovered gems that may be flying under most investors’ radar.

    Bausch + Lomb Investment Narrative Recap

    To own Bausch + Lomb, you need to accept a story built around long term demand for eye health across Vision Care, Pharma and Surgical, while the firm is still working toward consistent profitability. The Saunders exit and Thomas J. Appio’s interim appointment do not obviously change the near term focus on execution in dry eye therapies, premium lenses and consumer eye care.

    The key near term swing factor remains how effectively Bausch + Lomb turns its product breadth into higher quality earnings under the Vision 27 program. The biggest operational risk is that execution missteps, including any distraction from the CEO transition, could slow progress on margins at a time when the business is still reporting a net loss of US$171 million.

    The most relevant announcement here is the board’s move on October 12, 2026, to appoint Thomas J. Appio as interim CEO of Bausch + Lomb while he remains CEO of Bausch Health. That puts one leader over both entities, with direct oversight of Vision Care, Pharmaceuticals and Surgical at the same time the firm is pursuing margin expansion and profitability goals.

    For investors, the question is whether this dual role helps or complicates delivery on existing catalysts such as dry eye prescription momentum, premium IOL recovery and Vision 27 cost work. Execution on these areas, alongside managing higher risk funding that is entirely external borrowing, will likely matter more than the title change itself for how the BLCO story unfolds.

    Bausch + Lomb Forecasts And Analyst Assumptions

    Bausch + Lomb's consensus scenario points to revenues of US$6.4b and earnings of US$325.4m by 2029. That profile reflects analyst expectations for 6.2% yearly revenue growth and an earnings change of about US$496m from the current loss of US$171.0m.

    Uncover why Bausch + Lomb's fair value indicates an 11% potential upside to its current price that could narrow quickly.

    NYSE:BLCO 1-Year Stock Price Chart
    NYSE:BLCO 1-Year Stock Price Chart

    Exploring Other Perspectives

    Bullish analysts viewed Bausch + Lomb’s dry eye and surgical pipeline as the key upside catalyst, pencilling in about US$6.6b of revenue and US$558.3m of earnings by 2029, compared with the consensus US$6.4b and US$325.4m. You can treat the CEO shake up as a fresh test of those pre news assumptions and consider how views might shift.

    Explore 4 other Bausch + Lomb fair value estimates, including one that indicates the potential for up to 125% upside from the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and research.

    Looking For More Ideas Beyond Bausch + Lomb?

    If the Bausch + Lomb story has sharpened your thinking and you want to cast a wider net, the Simply Wall St Screener can help you quickly sort through other listed businesses that might fit your style, risk tolerance and return goals.